<DOC>
	<DOCNO>NCT00820976</DOCNO>
	<brief_summary>Background The effect granulocyte colony-stimulating factor ( G-CSF ) recovery follow induction chemotherapy widely accept . However , impact response survival clarify yet . Male gender claim susceptibility factor development leukemia shorten survival effect sex analyze clinical trial utilize G-CSF . Design Methods Efficacy safety G-CSF adjunct de novo AML remission induction therapy assess prospective randomized Phase III multicenter trial . Patients randomize receive induction therapy consist either cytosine arabinoside 100mg/m2/d , day 1-10 idarubicin 12 mg/m2/d , day 1-3 ( control arm ) plus G-CSF ( Filgrastim , 5 Âµg/kg/d start day 8 absolute neutrophil count ( ANC ) 0.5x109/L two consecutive day ) median duration 14 day ( G-CSF arm ) . After achievement CR , patient receive first consolidation course Ara-C 1 gr/sq.m/d ( d1-5 ) Ida 12 mg/sq.m/d ( d1-3 ) . If patient HLA identical donor randomize receive second course consolidation either high dose Ara-C 3 gr/sq.m/d ( d1 , 3 , 5 ) G-CSF collection stem cell consecutive PBSCT .</brief_summary>
	<brief_title>Induction With Without Granulocyte Colony-Stimulating Factor AML Transplantation AML</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Newly diagnose AML Age 16 Performance status great 60 Previously untreated Peripheral blood white blood cell ( WBC ) count le ( &lt; ) 0.5 x109/L , and/or marrow leukemic blast &lt; 20 % 7th day remission induction treatment Previously treat Acute promyelocytic leukemia Age equal young 15</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>G-CSF</keyword>
	<keyword>AML</keyword>
	<keyword>survival</keyword>
</DOC>